Last 12 months
Inside the activity.
1 purchase rows · 5 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2020 Filed Feb 29, 2020 00:22 UTC |
APPIO THOMASPres&Co-Head Bausch&Lomb/Int'l
|
GrantCommon Shares, No Par Value | 19,449 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-008434 · form4.xml · nonDerivative · entry 1 APPIO THOMAS · CIK 0001683323 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,165 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch Health Companies Inc. ("Bausch Health"). Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:19 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
GrantNon-qualified Stock Options (right To Purchase) · Derivative | 81,873 | $0.00 Strike: $24.77 | $0.00 |
DisclosureSEC source: 0001127602-20-008431 · form4.xml · derivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,873 Underlying: Common Shares, No Par Value · 81,873 shares Expires 2030-02-26 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:19 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
GrantCommon Shares, No Par Value | 19,449 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-008431 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,367 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch Health Companies Inc. ("Bausch Health"). Read SEC document |
| February 20, 2020 Filed Feb 22, 2020 02:58 UTC |
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'l
|
Tax withholdingCommon Shares, No Par Value | 11,703 | $26.46 | $309,661.38 |
DisclosureSEC source: 0001127602-20-007081 · form4.xml · nonDerivative · entry 3 Gordon Joseph F · CIK 0001749876 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,795 F4 · kind: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 20, 2020 Filed Feb 22, 2020 02:56 UTC |
Eldessouky SamSVP, CHIEF ACCOUNTING OFFICER
|
Tax withholdingCommon Stock, No Par Value | 8,943 | $26.46 | $236,631.78 |
DisclosureSEC source: 0001127602-20-007078 · form4.xml · nonDerivative · entry 3 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,917 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 20, 2020 Filed Feb 22, 2020 02:54 UTC |
APPIO THOMASPres&Co-Head Bausch&Lomb/Int'l
|
Tax withholdingCommon Stock, No Par Value | 9,866 | $26.46 | $261,054.36 |
DisclosureSEC source: 0001127602-20-007077 · form4.xml · nonDerivative · entry 3 APPIO THOMAS · CIK 0001683323 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,716 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 20, 2020 Filed Feb 22, 2020 02:52 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
Tax withholdingCommon Stock, No Par Value | 22,378 | $26.46 | $592,121.88 |
DisclosureSEC source: 0001127602-20-007076 · form4.xml · nonDerivative · entry 3 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,190 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 20, 2020 Filed Feb 25, 2020 01:54 UTC |
Humphries William D.President, Ortho-Dermatologics
|
Tax withholdingCommon Stock, No Par Value | 56,532 | $26.46 | $1,495,836.72 |
DisclosureSEC source: 0001127602-20-007430 · form4.xml · nonDerivative · entry 3 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,027 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:58 UTC |
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'l
|
Exercise / conversionRestricted Share Units · Derivative | 5,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007081 · form4.xml · derivative · entry 4 Gordon Joseph F · CIK 0001749876 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 5,242 shares Expires 2020-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. F2 · derivative.exercise_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F2 · derivative.expiration_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F5 · balance_after: This PSU award was previously reported on a Form 3 filed on August 10, 2018 with the target award amount of 5,461 shares. Any portion of the award not vested on February 19, 2020 was cancelled as of that date. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:58 UTC |
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'l
|
GrantCommon Shares, No Par Value | 28,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-007081 · form4.xml · nonDerivative · entry 2 Gordon Joseph F · CIK 0001749876 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,498 Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:58 UTC |
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'l
|
Exercise / conversionCommon Shares, No Par Value | 5,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007081 · form4.xml · nonDerivative · entry 1 Gordon Joseph F · CIK 0001749876 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person in connection with the vesting of performance-based Restricted Share Units ("PSUs") granted to the reporting person on January 6, 2017. F2 · shares: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:56 UTC |
Eldessouky SamSVP, CHIEF ACCOUNTING OFFICER
|
Exercise / conversionRestricted Share Units · Derivative | 4,096 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007078 · form4.xml · derivative · entry 4 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,096 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. F2 · derivative.exercise_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F2 · derivative.expiration_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F5 · balance_after: This PSU award was previously reported on a Form 4 filed on March 3, 2017 with the maximum potential award amount of 8,534 PSUs. Any portion of the award not vested on February 19, 2020 were cancelled as of that date. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:56 UTC |
Eldessouky SamSVP, CHIEF ACCOUNTING OFFICER
|
GrantCommon Stock, No Par Value | 22,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-007078 · form4.xml · nonDerivative · entry 2 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,860 Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:56 UTC |
Eldessouky SamSVP, CHIEF ACCOUNTING OFFICER
|
Exercise / conversionCommon Stock, No Par Value | 4,096 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007078 · form4.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person in connection with the vesting of performance-based Restricted Share Units ("PSUs") granted to the reporting person on January 6, 2017. F2 · shares: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:54 UTC |
APPIO THOMASPres&Co-Head Bausch&Lomb/Int'l
|
Exercise / conversionRestricted Share Units · Derivative | 3,932 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007077 · form4.xml · derivative · entry 4 APPIO THOMAS · CIK 0001683323 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,932 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. F2 · derivative.exercise_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F2 · derivative.expiration_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F5 · balance_after: This PSU award was previously reported on a Form 4 filed on January 10, 2017 with the maximum potential award amount of 8,192 shares. Any portion of the award not vested on February 19, 2020 was cancelled as of that date. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:54 UTC |
APPIO THOMASPres&Co-Head Bausch&Lomb/Int'l
|
GrantCommon Stock, No Par Value | 21,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-007077 · form4.xml · nonDerivative · entry 2 APPIO THOMAS · CIK 0001683323 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,582 Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:54 UTC |
APPIO THOMASPres&Co-Head Bausch&Lomb/Int'l
|
Exercise / conversionCommon Stock, No Par Value | 3,932 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007077 · form4.xml · nonDerivative · entry 1 APPIO THOMAS · CIK 0001683323 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person in connection with the vesting of performance-based Restricted Share Units ("PSUs") granted to the reporting person on January 6, 2017. F2 · shares: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:52 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
Exercise / conversionRestricted Share Units · Derivative | 7,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007076 · form4.xml · derivative · entry 4 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,864 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. F2 · derivative.exercise_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F2 · derivative.expiration_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F5 · balance_after: This PSU award was previously reported on a Form 4 filed on January 10, 2017 with the maximum potential award amount of 16,384 shares. Any portion of the award not vested on February 19, 2020 was terminated as of that date. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:52 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
GrantCommon Stock, No Par Value | 42,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-007076 · form4.xml · nonDerivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,568 Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:52 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
Exercise / conversionCommon Stock, No Par Value | 7,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007076 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person in connection with the vesting of performance-based Restricted Share Units ("PSUs") granted to the reporting person on January 6, 2017. F2 · shares: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document |
| February 19, 2020 Filed Feb 25, 2020 01:54 UTC |
Humphries William D.President, Ortho-Dermatologics
|
Exercise / conversionRestricted Share Units · Derivative | 20,911 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007430 · form4.xml · derivative · entry 4 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,911 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. F2 · derivative.exercise_date: On January 2, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F2 · derivative.expiration_date: On January 2, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F5 · balance_after: This PSU award was previously reported on a Form 4 filed on January 4, 2017 with the maximum potential award amount of 41,002 shares. Any portion of the award not vested on February 19, 2020 was cancelled as of that date. Read SEC document |
| February 19, 2020 Filed Feb 25, 2020 01:54 UTC |
Humphries William D.President, Ortho-Dermatologics
|
GrantCommon Stock, No Par Value | 105,783 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-007430 · form4.xml · nonDerivative · entry 2 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,559 Read SEC document |
| February 19, 2020 Filed Feb 25, 2020 01:54 UTC |
Humphries William D.President, Ortho-Dermatologics
|
Exercise / conversionCommon Stock, No Par Value | 20,911 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007430 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person in connection with the vesting of performance-based Restricted Share Units ("PSUs") granted to the reporting person on January 2, 2017. F2 · shares: On January 2, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document |
| February 19, 2020 Filed Feb 29, 2020 00:16 UTC Amendment |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
Exercise / conversionRestricted Share Units · Derivative | 7,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-008429 · form4a.xml · derivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,864 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F4 · price: Each PSU converts into Common Shares on a one-for-one basis. F2 · derivative.exercise_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F2 · derivative.expiration_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F5 · balance_after: This PSU award was previously reported on a Form 4 filed on January 10, 2017 with the maximum potential award amount of 16,384 shares. Any portion of the award not vested on February 19, 2020 was terminated as of that date. Read SEC document |
| February 19, 2020 Filed Feb 29, 2020 00:16 UTC Amendment |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
Exercise / conversionCommon Shares, No Par Value | 7,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-008429 · form4a.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person in connection with the vesting of performance-based Restricted Share Units ("PSUs") granted to the reporting person on January 6, 2017. F2 · shares: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F3 · shares: This Form 4/A is being filed solely to reflect the acquisition of 7,864 Common Shares instead of the disposition of Common Shares originally reported on the Form 4 filed on February 21, 2020. F4 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 21:17 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
Tax withholdingCommon Stock, No Par Value | 3,360 | $29.42 | $98,851.20 |
DisclosureSEC source: 0001127602-20-001361 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,165 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 21:24 UTC |
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'l
|
Tax withholdingCommon Shares, No Par Value | 2,118 | $29.42 | $62,311.56 |
DisclosureSEC source: 0001127602-20-001372 · form4.xml · nonDerivative · entry 1 Gordon Joseph F · CIK 0001749876 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,078 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 21:21 UTC |
Eldessouky SamSVP, CHIEF ACCOUNTING OFFICER
|
Tax withholdingCommon Stock, No Par Value | 1,694 | $29.42 | $49,837.48 |
DisclosureSEC source: 0001127602-20-001369 · form4.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,750 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 21:19 UTC |
APPIO THOMASPres&Co-Head Bausch&Lomb/Int'l
|
Tax withholdingCommon Stock, No Par Value | 1,827 | $29.42 | $53,750.34 |
DisclosureSEC source: 0001127602-20-001366 · form4.xml · nonDerivative · entry 1 APPIO THOMAS · CIK 0001683323 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,517 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 21:18 UTC |
Humphries William D.President, Ortho-Dermatologics
|
Tax withholdingCommon Stock, No Par Value | 14,559 | $29.92 | $435,605.28 |
DisclosureSEC source: 0001127602-20-001277 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,865 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 21:49 UTC |
WECHSLER AMY BDirector
|
GrantCommon Stock, No Par Value | 1,065 | $29.92 | $31,864.80 |
DisclosureSEC source: 0001127602-20-000201 · form4.xml · nonDerivative · entry 1 WECHSLER AMY B · CIK 0001677300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,874 F1 · shares: Reflects Restricted Share Units ("RSUs"), each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 21:47 UTC |
ROBERTSON RUSSEL CDirector
|
GrantCommon Stock, No Par Value | 1,253 | $29.92 | $37,489.76 |
DisclosureSEC source: 0001127602-20-000196 · form4.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,983 F1 · shares: Reflects Restricted Share Units ("RSUs"), each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 21:34 UTC |
Paulson JohnDirector
|
GrantCommon Stock, No Par Value | 919 | $29.92 | $27,496.48 |
DisclosureSEC source: 0001127602-20-000176 · form4.xml · nonDerivative · entry 1 Paulson John · CIK 0001394923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,712 F1 · shares: Reflects Restricted Share Units ("RSUs"), each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 21:29 UTC |
DE SCHUTTER RICHARD UDirector
|
GrantCommon Stock, No Par Value | 1,044 | $29.92 | $31,236.48 |
DisclosureSEC source: 0001127602-20-000165 · form4.xml · nonDerivative · entry 1 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,250 F1 · shares: Reflects Restricted Share Units ("RSUs"), each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 00:20 UTC |
APPIO THOMASPres&Co-Head Bausch&Lomb/Int'l
|
Tax withholdingCommon Stock, No Par Value | 3,337 | $31.00 | $103,447.00 |
DisclosureSEC source: 0001127602-19-035273 · form4.xml · nonDerivative · entry 1 APPIO THOMAS · CIK 0001683323 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,344 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:43 UTC |
WECHSLER AMY BDirector
|
GrantCommon Stock, No Par Value | 1,458 | $21.85 | $31,857.30 |
DisclosureSEC source: 0001127602-19-029786 · form4.xml · nonDerivative · entry 1 WECHSLER AMY B · CIK 0001677300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,809 F1 · shares: Reflects Restricted Share Units ("RSUs"), each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:41 UTC |
ROBERTSON RUSSEL CDirector
|
GrantCommon Stock, No Par Value | 1,716 | $21.85 | $37,494.60 |
DisclosureSEC source: 0001127602-19-029782 · form4.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,730 F1 · shares: Reflects Restricted Share Units ("RSUs"), each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:39 UTC |
Paulson JohnDirector
|
GrantCommon Stock, No Par Value | 1,258 | $21.85 | $27,487.30 |
DisclosureSEC source: 0001127602-19-029780 · form4.xml · nonDerivative · entry 1 Paulson John · CIK 0001394923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,793 F1 · shares: Reflects Restricted Share Units ("RSUs"), each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:33 UTC |
DE SCHUTTER RICHARD UDirector
|
GrantCommon Stock, No Par Value | 1,430 | $21.85 | $31,245.50 |
DisclosureSEC source: 0001127602-19-029777 · form4.xml · nonDerivative · entry 1 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,206 F1 · shares: Reflects Restricted Share Units ("RSUs"), each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 21:08 UTC |
PAPA JOSEPH CDirector · CHAIRMAN & CEO
|
Tax withholdingCommon Shares, No Par Value | 5,115 | $23.24 | $118,872.60 |
DisclosureSEC source: 0001127602-19-028755 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,734 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 21:05 UTC |
Herendeen PaulEVP and CFO
|
Tax withholdingCommon Stock, No Par Value | 1,642 | $23.24 | $38,160.08 |
DisclosureSEC source: 0001127602-19-028754 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,718 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| September 13, 2019 Filed Sep 14, 2019 01:06 UTC |
PAPA JOSEPH CDirector · CHAIRMAN & CEO
|
GrantCommon Shares, No Par Value | 21,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-028360 · form4.xml · nonDerivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 860,849 F1 · shares: Represents matching Restricted Share Units ("MRSUs") granted to the Reporting Person in connection with the open market purchase of Common Shares of the Issuer reported on Table I (the "Purchased Shares"), pursuant to the Issuer's Matching Share Program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant ("MRSU Grant Date"), subject to the Reporting Person's continued service (except in limited circumstances). Read SEC document |
| September 13, 2019 Filed Sep 14, 2019 01:06 UTC |
PAPA JOSEPH CDirector · CHAIRMAN & CEO
|
PurchaseCommon Shares, No Par Value | 30,000 | $23.31 | $699,300.00 |
DisclosureSEC source: 0001127602-19-028360 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 839,601 Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 20:07 UTC |
Herendeen PaulEVP and CFO
|
Tax withholdingCommon Stock, No Par Value | 24,625 | $22.40 | $551,600.00 |
DisclosureSEC source: 0001127602-19-027449 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,360 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:15 UTC |
McKenna Mark C.President, Salix
|
SaleCommon Shares, No Par Value | 10,773 | $21.83 | $235,220.91 |
DisclosureSEC source: 0001127602-19-027163 · form4.xml · nonDerivative · entry 1 McKenna Mark C. · CIK 0001749623 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,756 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.82 to $21.845 per share. The Reporting Person will provide to the Commission, the Issuer and any stockholder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range provided in this footnote. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:19 UTC |
APPIO THOMASPres&Co-Head Bausch&Lomb/Int'l
|
Tax withholdingCommon Stock, No Par Value | 8,362 | $21.30 | $178,110.60 |
DisclosureSEC source: 0001127602-19-027165 · form4.xml · nonDerivative · entry 1 APPIO THOMAS · CIK 0001683323 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,681 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 20:17 UTC |
Humphries William D.President, Ortho-Dermatologics
|
GrantCommon Stock, No Par Value | 30,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-027064 · form4.xml · nonDerivative · entry 2 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,424 F2 · shares: Represents matching Restricted Share Units ("MRSUs") granted to the Reporting Person in connection with the open market purchase of Common Shares of the Issuer reported on Table I (the "Purchased Shares"), pursuant to the Issuer's Matching Share Program. One-third of the MRSUs will vest on each of the first, second and third anniversaries following the date of grant ("MRSU Grant Date"), subject to the Reporting Person's continued service (except in limited circumstances). Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 20:17 UTC |
Humphries William D.President, Ortho-Dermatologics
|
PurchaseCommon Stock, No Par Value | 30,703 | $21.18 | $650,142.17 |
DisclosureSEC source: 0001127602-19-027064 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,721 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.13 to $21.18 per share. The Reporting Person will provide to the Commission, the Issuer and any stockholder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range provided in this footnote. Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 20:03 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
SaleCommon Stock, No Par Value | 3,418 | $22.45 | $76,725.56 |
DisclosureSEC source: 0001127602-19-026527 · form4.xml · nonDerivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,525 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price in Column 4 reflects the average weighted sale price for the transactions aggregated on this Form 4. The sales price per share reported on this Form 4 range from $22.30 to $22.61. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 20:03 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
Tax withholdingCommon Stock, No Par Value | 7,779 | $22.39 | $174,171.81 |
DisclosureSEC source: 0001127602-19-026527 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,943 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.